« Return to News | Drug Sponsors

Lunudbeck to invest $16 million in Proximagen

Thursday, September 29, 2011 01:00 PM

Danish pharmaceutical group Lundbeck is to invest $6.1 million in British peer Proximagen Group as part of a strategic partnership, the companies said, according to Reuters.

Entering the deal would allow the companies to jointly use their expertise in central nervous system (CNS) drug development, the companies said in a statement.

"Proximagen has built an exciting pipeline which offers real promise in treating a number of CNS disorders," Lundbeck's head of research and development, Anders Gersel Pedersen said.

"This strategic partnership will provide Lundbeck with exposure to some very exciting research programs," Pedersen said.

As part of the deal, a committee involving experts from both companies will focus on developing three of Proximagen's programs, with the aim of identifying new therapies for diseases such as epilepsy, pain and inflammatory disorders, the companies said.

Lundbeck would receive certain negotiation rights in relation to these programs, it said.

"The partnership with Lundbeck validates our strategy and represents a major step forward in realizing the value of key compounds in our pipeline," Proximagen's chief executive officer, Kenneth Mulvany, said.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.